scispace - formally typeset
P

Patrick Legembre

Researcher at French Institute of Health and Medical Research

Publications -  85
Citations -  7002

Patrick Legembre is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Fas receptor & Signal transduction. The author has an hindex of 29, co-authored 85 publications receiving 5711 citations. Previous affiliations of Patrick Legembre include University of Limoges & University of Rennes.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells.

Bryan C. Barnhart, +5 more
- 04 Aug 2004 - 
TL;DR: The data suggest that CD95L, which is found elevated in many human cancer patients, has tumorigenic activities on human cancer cells, and could become highly relevant during chemotherapy, which can cause upregulation of CD95 ligand by both tumor and nontumor cells.
Journal ArticleDOI

Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy.

Susan E. Logue, +18 more
- 15 Aug 2018 - 
TL;DR: It is shown that inhibition of IRE1’s RNase activity attenuates autocrine and paracrine signaling of pro-tumorigenic cytokines and synergizes with paclitaxel to confer potent anti-t tumor effects in TNBC.
Journal ArticleDOI

Two CD95 tumor classes with different sensitivities to antitumor drugs.

Alicia Algeciras-Schimnich, +6 more
- 30 Sep 2003 - 
TL;DR: A soluble form of CD95 ligand (S2) that is cytotoxic to type II cells but does not kill type I cells is identified, which suggests that type I and II tumor cells represent different stages of carcinogenesis that resemble the epithelial–mesenchymal transition.
Journal ArticleDOI

Does CD95 have tumor promoting activities

Marcus E. Peter, +2 more
- 25 May 2005 - 
TL;DR: A new model of CD95 functions is proposed in which CD95 is converted from a tumor suppressor to a tumor promotor by a single point mutation in one of the CD95 alleles, a situation frequently found in advanced human cancer, resulting in apoptosis resistance and activation of tumorigenic pathways.